A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.
Also called NCT04252287
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 476 participants
- Registry
-
NCT04252287
-
- Other papers using this trial's data
- Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure
- Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin
- Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial
- The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04252287. Randomized; double masking; primary purpose treatment. Start 2020-03-10 (actual); primary completion 2021-11-09 (actual). Results posted on 2023-01-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
- Acronym
- CHIEF-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Canagliflozin 100 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct04252287- Content hash
cbc223a1b653696262e51439bd04845f6bd13d5a44739cc0c6b1907e5416012e